| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 701,170 | 1,118,211 | ||
| Total operating expenses | 701,170 | 1,118,211 | ||
| Loss from operations | -701,170 | -1,118,211 | ||
| Interest expense, related parties | 19,052 | 62,288 | ||
| Interest income | - | 24,383 | ||
| Forgiveness of unrelated vendor payables | - | 2,142,297 | ||
| Change in fair value of deferred underwriting fee - common stock payable | 560,000 | -756,000 | ||
| Change in the fair value of warrant liabilities | -76,871 | 116,894 | ||
| Loss on exchange of common stock for warrants | -1,740,000 | - | ||
| Total other income (expense), net | -1,122,181 | 1,231,498 | ||
| Net loss | -1,823,351 | 113,287 | ||
| Earnings per share, basic | -0.07 | 0 | ||
| Earnings per share, diluted | -0.07 | 0 | ||
| Weighted average number of shares outstanding, basic | 27,007,568 | 23,301,178 | ||
| Weighted average number of shares outstanding, diluted | 27,007,568 | 23,301,178 | ||
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)